Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher remission (HAM‐D total score ≤ 7) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to lower incidence of SAD (SIGH‐SAD score ≥ 20) compared with placebo (moderate certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Headache · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review
Insomnia · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher insomnia compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Incidence of SAD (modified ITT) · adults with a history of SAD
It is very uncertain whether agomelatine changes incidence of SAD (modified ITT) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event subjective and objective · adults with a history of SAD
It is very uncertain whether agomelatine changes number of persons with at least one adverse event within a year compared with placebo (very low certainty).
1 finding from 1 review
Severity of depression (SIGH‐SAD score) at the end of the study · adults with a history of SAD
1 finding from 1 review
Quality of life · adults with a history of SAD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of interpersonal and social functioning · adults with a history of SAD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing at least one severe adverse event · adults with a history of SAD
It is very uncertain whether agomelatine changes number of persons with at least one severe adverse event within a year compared with placebo (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
Antidepressant showed no clear difference in improvement in depression: HAM‐D score at 6‐12 weeks (dichotomized) compared with placebo (low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
Antidepressant showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with placebo (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
Antidepressant showed no clear difference in study dropouts at 6‐12 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether antidepressant changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Quality of life score at 8 weeks · adults living with HIV and depression
1 finding from 1 review